학술논문
Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06)
Document Type
Article
Author
Source
In Annals of Oncology January 2011 22(1):80-85
Subject
Language
ISSN
0923-7534